68 related articles for article (PubMed ID: 38589002)
21. Monocyte bioenergetics: An immunometabolic perspective in metabolic dysfunction-associated steatohepatitis.
Sangineto M; Ciarnelli M; Colangelo T; Moola A; Bukke VN; Duda L; Villani R; Romano A; Giandomenico S; Kanwal H; Serviddio G
Cell Rep Med; 2024 May; 5(5):101564. PubMed ID: 38733988
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
United European Gastroenterol J; 2024 Jun; ():. PubMed ID: 38894596
[TBL] [Abstract][Full Text] [Related]
23. Liver and pancreatic-targeted interleukin-22 as a therapeutic for metabolic dysfunction-associated steatohepatitis.
Sajiir H; Keshvari S; Wong KY; Borg DJ; Steyn FJ; Fercher C; Taylor K; Taylor B; Barnard RT; Müller A; Moniruzzaman M; Miller G; Wang R; Fotheringham A; Schreiber V; Sheng YH; Hancock JL; Loo D; Burr L; Huynh T; Lockett J; Ramm GA; Macdonald GA; Prins JB; McGuckin MA; Hasnain SZ
Nat Commun; 2024 May; 15(1):4528. PubMed ID: 38811532
[TBL] [Abstract][Full Text] [Related]
24. Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?
Sokal-Dembowska A; Jarmakiewicz-Czaja S; Ferenc K; Filip R
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791276
[TBL] [Abstract][Full Text] [Related]
25. Circulating Neutrophil Profiles Undergo a Dynamic Shift during Metabolic Dysfunction-Associated Steatohepatitis (MASH) Progression.
Maretti-Mira AC; Salomon MP; Chopra S; Yuan L; Golden-Mason L
Biomedicines; 2024 May; 12(5):. PubMed ID: 38791066
[TBL] [Abstract][Full Text] [Related]
26. Metabolic reprogramming in liver fibrosis.
Horn P; Tacke F
Cell Metab; 2024 May; ():. PubMed ID: 38823393
[TBL] [Abstract][Full Text] [Related]
27. The lipopolysaccharide-TLR4 axis regulates hepatic glutaminase 1 expression promoting liver ammonia build-up as steatotic liver disease progresses to steatohepatitis.
Mercado-Gómez M; Goikoetxea-Usandizaga N; Kerbert AJC; Gracianteparaluceta LU; Serrano-Maciá M; Lachiondo-Ortega S; Rodriguez-Agudo R; Gil-Pitarch C; Simón J; González-Recio I; Fondevila MF; Santamarina-Ojeda P; Fraga MF; Nogueiras R; Heras JL; Jalan R; Martínez-Chantar ML; Delgado TC
Metabolism; 2024 Jun; 158():155952. PubMed ID: 38906371
[TBL] [Abstract][Full Text] [Related]
28. Tectorigenin improves metabolic dysfunction-associated steatohepatitis by down-regulating tRF-3040b and promoting mitophagy to inhibit pyroptosis pathway.
Zhu J; Tang W; Wu X; Mu M; Zhang Q; Zhao X
Biochem Biophys Res Commun; 2024 Aug; 720():150118. PubMed ID: 38776757
[TBL] [Abstract][Full Text] [Related]
29. Low MBOAT7 expression, a genetic risk for MASH, promotes a pro-fibrotic pathway involving hepatocyte TAZ upregulation.
Moore MP; Wang X; Kennelly JP; Shi H; Ishino Y; Kano K; Aoki J; Cherubini A; Ronzoni L; Guo X; Chalasani NP; Khalid S; Saleheen D; Mitsche MA; Rotter JI; Yates KP; Valenti L; Kono N; Tontonoz P; Tabas I
Hepatology; 2024 May; ():. PubMed ID: 38776184
[TBL] [Abstract][Full Text] [Related]
30. Hepatic glucagon action: beyond glucose mobilization.
Kajani S; Laker RC; Ratkova E; Will S; Rhodes CJ
Physiol Rev; 2024 Jul; 104(3):1021-1060. PubMed ID: 38300523
[TBL] [Abstract][Full Text] [Related]
31. A High-Fat and High-Fructose Diet Exacerbates Liver Dysfunction by Regulating Sirtuins in a Murine Model.
Ding Z; Zhang J; Choudhury M
Life (Basel); 2024 Jun; 14(6):. PubMed ID: 38929712
[TBL] [Abstract][Full Text] [Related]
32. Tumour extracellular vesicles and particles induce liver metabolic dysfunction.
Wang G; Li J; Bojmar L; Chen H; Li Z; Tobias GC; Hu M; Homan EA; Lucotti S; Zhao F; Posada V; Oxley PR; Cioffi M; Kim HS; Wang H; Lauritzen P; Boudreau N; Shi Z; Burd CE; Zippin JH; Lo JC; Pitt GS; Hernandez J; Zambirinis CP; Hollingsworth MA; Grandgenett PM; Jain M; Batra SK; DiMaio DJ; Grem JL; Klute KA; Trippett TM; Egeblad M; Paul D; Bromberg J; Kelsen D; Rajasekhar VK; Healey JH; Matei IR; Jarnagin WR; Schwartz RE; Zhang H; Lyden D
Nature; 2023 Jun; 618(7964):374-382. PubMed ID: 37225988
[TBL] [Abstract][Full Text] [Related]
33. Antigen-driven CD8
Burtis AEC; DeNicola DMC; Ferguson ME; Santos RG; Pinilla C; Kriss MS; Orlicky DJ; Tamburini BAJ; Gillen AE; Burchill MA
bioRxiv; 2024 Mar; ():. PubMed ID: 38562766
[TBL] [Abstract][Full Text] [Related]
34. The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1.
Li Y; Chen L; Sottas C; Raul MC; Patel ND; Bijja JR; Ahmed SK; Kapelanski-Lamoureux A; Lazaris A; Metrakos P; Zambidis A; Chopra S; Li M; Sugahara G; Saito T; Papadopoulos V
Metabolism; 2024 Jun; ():155942. PubMed ID: 38871077
[TBL] [Abstract][Full Text] [Related]
35. Spatial transcriptomics unravels palmitoylation and zonation-dependent gene regulation by AEG-1 in mouse liver.
Saverino A; Qu X; Mendoza RG; Raha S; Manna D; Ermi AG; Subler MA; Windle JJ; Liu J; Sarkar D
J Biol Chem; 2024 Apr; 300(6):107322. PubMed ID: 38677511
[TBL] [Abstract][Full Text] [Related]
36. Resmetirom for treatment of MASH.
Sookoian S; Pirola CJ
Cell; 2024 Jun; 187(12):2897-2897.e1. PubMed ID: 38848671
[TBL] [Abstract][Full Text] [Related]
37. Hope on the Horizon: Promising Therapies for Steatotic Liver Disease.
Sahebkar A; Eid AH
Pharmacol Rev; 2024 Jun; 76(4):561-563. PubMed ID: 38876495
[TBL] [Abstract][Full Text] [Related]
38. An evolutionary trade-off between host immunity and metabolism drives fatty liver in male mice.
Nikkanen J; Leong YA; Krause WC; Dermadi D; Maschek JA; Van Ry T; Cox JE; Weiss EJ; Gokcumen O; Chawla A; Ingraham HA
Science; 2022 Oct; 378(6617):290-295. PubMed ID: 36264814
[TBL] [Abstract][Full Text] [Related]
39. Activation of hepatic adenosine A1 receptor ameliorates MASH via inhibiting SREBPs maturation.
Zhu W; Hong Y; Tong Z; He X; Li Y; Wang H; Gao X; Song P; Zhang X; Wu X; Tan Z; Huang W; Liu Z; Bao Y; Ma J; Zheng N; Xie C; Ke X; Zhou W; Jia W; Li M; Zhong J; Sheng L; Li H
Cell Rep Med; 2024 May; 5(5):101563. PubMed ID: 38718795
[No Abstract] [Full Text] [Related]
40. Ablation of IFNγ in myeloid cells suppresses liver inflammation and fibrogenesis in mice with hepatic small heterodimer partner (SHP) deletion.
Zhu L; Litts B; Wang Y; Rein JA; Atzrodt CL; Chinnarasu S; An J; Thorson AS; Xu Y; Stafford JM
Mol Metab; 2024 May; 83():101932. PubMed ID: 38589002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
